Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Imatinib-Resistant/Intolerant CML and Ph+ ALL
NCT00529763Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Primary completion
- Jun 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Bristol Myers Squibb. Started Nov 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00529763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00529763.